Jeff Aronin
Co-founder, Chairman and CEO
Evozyne believes in the natural ability of evolution to solve today’s most demanding problems. Our mission is to make novel proteins that can solve longstanding challenges in therapeutics and sustainability. We combine the principles of evolution and deep learning technology to make advanced-functioning novel proteins today that would otherwise take nature millions of years to create. By elevating a protein’s performance to unprecedented levels, Evozyne enables commercial-scale solutions that pave the way for new products and new markets while contributing to a healthier, more sustainable world. We are located in Chicago and recently completed a 30,000 square foot office and lab space at our headquarters in the Lincoln Park neighborhood.
Co-founder, Chairman and CEO
M.D., Ph.D.
Co-founder and Chief Scientific Officer
MBA
Chief Business Officer
Ph.D.
SVP Commercial
Ph.D.
Co-founder and Computational Lead
Ph.D.
VP Technology
Ph.D.
VP Protein Engineering
VP Talent
Ph.D.
VP Product & Strategy
Ph.D.
VP Operations
General Counsel
Ph.D. Evozyne SAB Chair
Dean of the Pritzker School of Molecular Engineering (PME) and the Robert A. Millikan Distinguished Service Professor at the University of Chicago.
Ph.D.
T.Z. and Irmgard Chu Distinguished Chair in Chemistry at University of California, Berkeley.
Ph.D.
Professor at the Organic Chemistry Laboratory of ETH Zurich.
Ph.D.
Assistant Professor of Genetic and Bioengineering and fellow of the ChEM-H Institute at Stanford.
Ph.D.
Chancellor's Professor at the University of California, Berkeley in the departments of Molecular and Cell Biology and Chemistry.
Ph.D.
Professor at the California Institute of Technology, William K. Bowes Jr. Leadership Chair in the Division of Biology and Biological Engineering, and the Bren Professor of Biology and Chemistry.
Evozyne was founded by Paragon Biosciences, a top innovator whose mission is to solve complex human and societal challenges by accelerating development of novel therapies and life science breakthroughs. Evozyne is well‑funded by additional top‑tier investors.